Cytomegalovirus

Principles and Practice of Clinical Virology: Sixth Edition

Volumn , Issue , 2009, Pages 161-197

  Griffiths, Paul D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cell mediated immunity; CMV one of the most successful human parasites; Congenital CMV infection highest incidence in poorer communities; Cytomegalovirus (CMV) infections and cytopathic effect (CPE); Genome expression control; HCMV envelope glycoproteins; Tissue immunofluorescence

Indexed keywords

EID: 84865386962     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470741405.ch8     Document Type: Chapter

References (131)

1. Adler, S.P., Finney, J.W., Manganello, A.M. and Best, A.M. (2004) Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. The Journal of Pediatrics, 145 (4), 485-91.
2. Balfour, H.H., Jr., Chace, B.A., Stapleton, J.T. et al. (1989) A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. The New England Journal of Medicine, 320 (21), 1381-87.
3. Barbi, M., Binda, S. and Caroppo, S. (2006) Diagnosis of congenital CMV infection via dried blood spots. Reviews in Medical Virology, 16 (6), 385-92.
4. Barkholt, L., PLewensohn-Fuchs, I., Ericzon, B.G. et al. (1999) High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis, 1 (2), 89-97.
5. Baskar, J.F., Smith, P.P., Ciment, G.S. et al. (1996) Developmental analysis of the cytomegalovirus enhancer in transgenic animals. Journal of Virology, 70 (5), 3215-26.
6. Boeckh, M., Gooley, T.A., Myerson, D. et al. (1996) Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88 (10), 4063-71.
7. Boppana, S.B. and Britt, W.J. (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. The Journal of Infectious Diseases, 171 (5), 1115-21.
8. Bowen, E.F., Wilson, P., Cope, A. et al. (1996) Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS , 10 (13), 1515-20.
9. Bowen, E.F., Sabin, C.A., Wilson, P. et al. (1997) Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS , 11 (7), 889-93.
10. Bradford, R.D., Cloud, G., Lakeman, A.D. et al. (2005) Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. The Journal of Infectious Diseases, 191 (2), 227-33.
11. Bresnahan, W.A. and Shenk, T. (2000) A subset of viral transcripts packaged within human cytomegalovirus particles. Science, 288 (5475), 2373-76.
12. Britt, W.J., Vugler, L., Butfiloski, E.J. and Stephens, E.B. (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology, 64 (3), 1079-85.
13. Cha, T.A., Tom, E., Kemble, G.W. et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. Journal of Virology, 70 (1), 78-83.
14. Chee, M.S., Bankier, A.T., Beck, S. et al. (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Current Topics in Microbiology and Immunology, 154, 125-69.
15. Cheeseman, S.H., Rubin, R.H., Stewart, J.A. et al. (1979) Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. The New England Journal of Medicine, 300 (24), 1345-49.
16. Chou, S., Van Wechel, L.C., Lichy, H.M. and Marousek, G.I. (2005) Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrobial Agents and Chemotherapy, 49 (7), 2710-15.
17. Chou, S., Van Wechel, L.C. and Marousek, G.I. (2007) Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. The Journal of Infectious Diseases, 196 (1), 91-94.
18. Cope, A.V., Sabin, C., Burroughs, A. et al. (1997a) Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. The Journal of Infectious Diseases, 176 (6), 1484-90.
19. Cope, A.V., Sweny, P., Sabin, C. et al. (1997b) Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. Journal of Medical Virology, 52 (2), 200-5.
20. Deayton, J., Mocroft, A., Wilson, P. et al. (1999) Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS , 13 (10), 1203-6.
21. Deayton, J., Sabin, C., Johnson, M., Emery, V., Wilson, P. and Griffiths, P. (2004) Importance of cytomegalovirus viraemia in risk of disease progression and dealth in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, 363 (9427) 2116-21.
22. Dieterich, D.T., Kotler, D.P., Busch, D.F. et al. (1993) Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, doubleblind, placebo-controlled multicenter study. The Journal of Infectious Diseases, 167 (2), 278-82.
23. Dolan, A., Cunningham, C., Hector, R.D. et al. (2004) Genetic content of wild-type human cytomegalovirus. The Journal of General Virology, 85 (Pt 5), 1301-12.
24. Dollard, S.C., Grosse, S.D. and Ross, D.S. (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in Medical Virology, 17 (5), 355-63.
25. Doniger, J., Muralidhar, S., Rosenthal, L.J. (1999) Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev, 12 (3), 367-82.
26. Einsele, H., Ehninger, G., Hebart, H. et al. (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 86 (7), 2815-20.
27. Emery, V.C. (2001) Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol , 11 (2), 83-6.
28. Emery, V.C., Cope, A.V., Bowen, E.F. et al. (1999) The dynamics of human cytomegalovirus replication in vivo. The Journal of Experimental Medicine, 190 (2), 177-82.
29. Emery, V.C. and Griffiths, P.D. (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 97 (14), 8039-44.
30. Feinberg, J.E., Hurwitz, S., Cooper, D. et al. AIDS Clinical Trials Group Protocol 204/GlaxoWellcome 123-014 International CMV Prophylaxis Study Group. (1998) A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. The Journal of Infectious Diseases, 177 (1), 48-56.
31. Fisher, S., Genbacev, O., Maidki, E. and Pereira, L. (2000) Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. Journal of Virology, 74 (15), 6808-20.
32. Fortunato, E.A. and Spector, D.H. (2003) Viral induction of site-specific chromosome damage. Reviews in Medical Virology, 13 (1), 21-37.
33. Fowler, K.B., Stagno, S. and Pass, R.F. (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. The Journal of the American Medical Association, 289 (8), 1008-11.
34. Fowler, K.B., Stagno, S. and Pass, R.F. (2004) Interval between births and risk of congenital cytomegalovirus infection. Clinical Infectious Diseases, 38 (7), 1035-37.
35. Fowler, K.B., Stagno, S., Pass, R.F. et al. (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. The New England Journal of Medicine, 326 (10), 663-67.
36. Gane, E., Saliba, F., Valdecasas, G.J. et al. The Oral Ganciclovir International Transplantation Study Group [corrected] (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet, 350 (9093), 1729-33.
37. Ghazal, P., Nelson, J. (1993) Interaction between cytomegalovirus immediate-early proteins and the long terminal repeat of human immunodeficiencey virus. Reviews in Medical Virology, 3 (1), 47-55.
38. Gilbert, G.L., Hayes, K., Hudson, I.L. and James, J., Neonatal Cytomegalovirus Infection Study Group (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet, 1 (8649), 1228-31.
39. Gleaves, C.A., Smith, T.F., Shuster, E.A. and Pearson, G.R. (1984) Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. Journal of Clinical Microbiology, 19 (6), 917-19.
40. Goodrich, J.M., Bowden, R.A., Fisher, L. et al. (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Annals of Internal Medicine, 118 (3), 173-78.
41. Goodrich, J.M., Mori, M., Gleaves, C.A. et al. (1991) Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. The New England Journal of Medicine, 325 (23), 1601-7.
42. Gor, D., Sabin, C., Prentice, H.G. et al. (1998) Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplantation, 21 (6), 597-605.
43. Gretch, D.R., Kari, B., Rasmussen, L. et al. (1988) Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. Journal of Virology, 62 (3), 875-81.
44. Griffiths, P.D. (1984) Diagnostic techniques for cytomegalovirus infection. Clinics in Haematology, 13 (3), 631-44.
45. Griffiths, P.D. (1998) Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo. The Journal of General Virology, 79 (Pt 2), 213-20.
46. Griffiths, P.D. and Baboonian, C. (1984) A prospective study of primary cytomegalovirus infection during pregnancy: final report. British Journal of Obstetrics and Gynaecology, 91 (4), 307-15.
47. Griffiths, P.D., Feinberg, J.E., Fry, J. et al. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group (1998) The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. The Journal of Infectious Diseases, 177 (1), 57-64.
48. Griffiths, P.D., McLean, A. and Emery, V.C. (2001) Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine, 19 (11-12), 1356-62.
49. Griffiths, P.D., Panjwani, D.D., Stirk, P.R. et al. (1984) Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet, 2 (8414), 1242-45.
50. Grob, J.P., Grundy, J.E., Prentice, H.G. et al. (1987) Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet, 1 (8536), 774-76.
51. Grundy, J.E., Lui, S.F., Super, M. et al. (1988) Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet, 2 (8603), 132-35.
52. Guerra, B., Lazzarotto, T., Quarta, S. et al. (2000) Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. American Journal of Obstetrics and Gynecology, 183 (2), 476-82.
53. Guerra, B., Simonazzi, G., Banfi, A. et al. (2007) Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers. American Journal of Obstetrics and Gynecology, 196 (3), 221-26.
54. Hart, G.D., Paya, C.V. (2001) Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol , 11 (2), 73-81.
55. Hamprecht, K., Maschmann, J., Vochem, M. et al. (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet, 357 (9255), 513-18.
56. + cytotoxic lymphocyte responses against cytomegalovirus after liver transplantation: correlation with time from transplant to receipt of tacrolimus. J Infect Dis, 15 (183/6), 835-43.
57. Hirsch, M.S., Schooley, R.T., Cosimi, A.B. et al. (1983) Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. The New England Journal of Medicine, 308 (25), 1489-93.
58. Hu, H., Jabs, D.A., Forman, M.S. et al. (2002) Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. The Journal of Infectious Diseases, 185 (7), 861-67.
59. Huang, E.S., Alford, C.A., Reynolds, D.W. et al. (1980) Molecular epidemiology of cytomegalovirus infections in women and their infants. The New England Journal of Medicine, 303 (17), 958-62.
60. Keller, R., Peitchel, R., Goldman, J.N. and Goldman, M. (1976) An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts. Journal of Immunology, 116 (3), 772-77.
61. Khoury, J.A., Storch, G.A., Bohl, D.L. et al. (2006) Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. American Journal of Transplantation, 6 (9), 2134-43.
62. Kidd, I.M., Fox, J.C., Pillay, D. et al. (1993) Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation, 56 (4), 867-71.
63. Kim, W.R., Badley, A.D., Wiesner, R.H. et al. (2000) The economic impact of cytomegalovirus infection after liver transplantation. Transplantation, 69 (3), 357-61.
64. Kimberlin, D.W., Lin, C.Y., Sanchez, P.J. et al. (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. The Journal of Pediatrics, 143 (1), 16-25.
65. Kondo, K., Kaneshima, H. and Mocarski, E.S. (1994) Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proceedings of the National Academy of Sciences of the United States of America, 91 (25), 11879-83.
66. Kotenko, S.V., Saccani, S., Izotova, L.S. et al. (2000) Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proceedings of the National Academy of Sciences of the United States of America, 97 (4), 1695-700.
67. Limaye, A.P., Corey, L., Koelle, D.M. et al. (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 356 (9230), 645-9.
68. Lowance, D., Neumayer, H.H., Legendre, C.M. et al. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. The New England Journal of Medicine, 340 (19), 1462-70.
69. Lui, S.F., Ali, A.A., Grundy, J.E. et al. (1992) Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrology, Dialysis, Transplantation, 7 (12), 1230-37.
70. Macdonald, P.S., Keogh, A.M., Marshman, D. et al. (1995) A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. The Journal of Heart and Lung Transplantation, 14 (1 Pt 1), 32-38.
71. Maidji, E., McDonagh, S., Genbacev, O. et al. (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol , 168 (4), 1210-26.
72. Mattes, F.M., Hainsworth, E.G., Geretti, A.M. et al. (2004) A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis, 189 (8), 1355-61.
73. Mattes, F.M., Hainsworth, E.G., Geretti, A.M. et al. (2004) A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. The Journal of Infectious Diseases, 189 (8), 1355-61.
74. Mattes, F.M., McLaughlin, J.E., Emery, V.C. et al. (2000) Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7. Journal of Clinical Pathology, 53 (8), 612-14.
75. Merigan, T.C., Renlund, D.G., Keay, S. et al. (1992) A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. The New England Journal of Medicine, 326 (18), 1182-86.
76. Metselaar, H.J., Rothbarth, P.H., Brouwer, R.M. et al. (1989) Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation, 48 (2), 264-66.
77. Meyers, J.D., Ljungman, P. and Fisher, L.D. (1990) Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. The Journal of Infectious Diseases, 162 (2), 373-80.
78. Moreno, T.N., Fortunato, E.A., Hsia, K. et al. (1997) A model system for human cytomegalovirus-mediated modulation of human immunodeficiency virus type 1 long terminal repeat activity in brain cells. J Virol, 71 (5), 3693-701.
79. Moretti, S., Zikos, P., Van Lint, M.T. et al. (1998) Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplantation, 22 (2), 175-80.
80. Muranyi, W., Haas, J., Wagner, M. et al. (2002) Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science, 297 (5582), 854-57.
81. Noyola, D.E., Demmler, G.J., Nelson, C.T. et al. (2001) Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. The Journal of Pediatrics, 138 (3), 325-31.
82. Pari, G.S., Kacica, M.A. and Anders, D.G. (1993) Open reading frames UL44, IRS1/TRS1, and UL36-38 are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA synthesis. Journal of Virology, 67 (5), 2575-82.
83. Pass, R.F., Hutto, C., Stagno, S. et al. (1986) Congenital cytomegalovirus infection: prospects for prevention. Annals of the New York Academy of Sciences, 477, 123-27.
84. Pass, R.F., Stagno, S., Britt, W.J. and Alford, C.A. (1983) Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. The Journal of Infectious Diseases, 148 (6), 953-61.
85. Paya, C.V., Wilson, J.A., Espy, M.J. et al. (2002) Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. The Journal of Infectious Diseases, 185 (7), 854-60.
86. Pescovitz, M.D., Rabkin, J., Merion, R.M. et al. (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents and Chemotherapy, 44 (10), 2811-15.
87. Pignatelli, S., Dal Monte, P., Rossini, G. and Landini, M.P. (2004) Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Reviews in Medical Virology, 14 (6), 383-410.
88. Pleskoff, O., Treboute, C., Brelot, A. et al. (1997) Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science, 276 (5320), 1874-78.
89. Plotkin, S.A., Starr, S.E., Friedman, H.M. et al. (1991) Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Annals of Internal Medicine, 114 (7), 525-31.
90. Prentice, H.G., Gluckman, E., Powles, R.L. et al. European Acyclovir for CMV Prophylaxis Study Group (1994) Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet, 343 (8900), 749-53.
91. Rayes, N., Seehofer, D., Schmidt, C.A. et al. (2001) Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation, 72 (5), 881-85.
92. Razonable, R.R., Brown, R.A., Wilson, J. et al. (2002) The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation, 73 (6), 968-73.
93. Reed, E.C., Wolford, J.L., Kopecky, K.J. et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Annals of Internal Medicine, 112 (7), 505-10.
94. Reusser, P., Einsele, H., Lee, J. et al. (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 99 (4), 1159-64.
95. Revello, M.G., Sarasini, A., Zavattoni, M. et al. (1998) Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction. Journal of Medical Virology, 56 (1), 99-103.
96. Roback, J.D. (2002) CMV and blood transfusions. Reviews in Medical Virology, 12 (4), 211-19.
97. Sagedal, S., Nordal, K.P., Hartmann, A. et al. (2003) Preemptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrology, Dialysis, Transplantation, 18 (9), 1899-908.
98. Schleiss, M.R. (2006) Acquisition of human cytomegalovirus infection in infants via breast milk: natural immunization or cause for concern? Reviews in Medical Virology, 16 (2), 73-82.
99. Schleiss, M.R. and Heineman, T.C. (2005) Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Review of Vaccines, 4 (3), 381-406.
100. Schmidt, G.M., Horak, D.A., Niland, J.C. et al. The City of Hope-Stanford-Syntex CMV Study Group (1991) A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The New England Journal of Medicine, 324 (15), 1005-11.
101. Shinkai, M., Bozzette, S.A., Powderly, W. et al. (1997) Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. The Journal of Infectious Diseases, 175 (2), 302-8.
102. Singh, N. (2006) Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Reviews in Medical Virology, 16 (5), 281-87.
103. Singh, I.P., Baron, S. (2000) Innate defences against viraemia. Rev Med Virol , 10 (6), 395-403.
104. Snydman, D.R. (2006) The case for cytomegalovirus prophylaxis in solid organ transplantation. Reviews in Medical Virology, 16 (5), 289-95.
105. Snydman, D.R., Werner, B.G., Dougherty, N.N. et al. The Boston Center for Liver Transplantation CMVIG Study Group (1993) Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 119 (10), 984-91.
106. Soderberg-Naucler, C., Fish, K.N. and Nelson, J.A. (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 91 (1), 119-26.
107. Spector, S.A., McKinley, G.F., Lalezari, J.P. et al. Roche Cooperative Oral Ganciclovir Study Group (1996) Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. The New England Journal of Medicine, 334 (23), 1491-97.
108. Spiller, O.B., Hanna, S.M., Devine, D.V., Tufaro, F. (1997) Neutralization of cytomegalovirus virions: the role of complement. J Infect Dis, 176 (2), 339-47.
109. Stagno, S., Pass, R.F., Cloud, G. et al. (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. The Journal of the American Medical Association, 256 (14), 1904-8.
110. Stagno, S., Reynolds, D.W., Pass, R.F. and Alford, C.A. (1980) Breast milk and the risk of cytomegalovirus infection. The New England Journal of Medicine, 302 (19), 1073-76.
111. Stagno, S., Reynolds, D.W., Tsiantos, A. et al. (1975a) Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. The Journal of Infectious Diseases, 132 (5), 568-77.
112. Stagno, S., Reynolds, D., Tsiantos, A. et al. (1975b) Cervical cytomegalovirus excretion in pregnant and nonpregnant women: suppression in early gestation. The Journal of Infectious Diseases, 131 (5), 522-27.
113. Stenberg, R.M. and Stinski, M.F. (1985) Autoregulation of the human cytomegalovirus major immediate-early gene. Journal of Virology, 56 (3), 676-82.
114. Stratton, K.R., Durch, J.S. and Lawrence, R.S. (2000) Vaccines for the 21st Century, National Academy Press, Washington, DC.
115. Streblow, D.N., Soderberg-Naucler, C., Vieira, J. et al. (1999) The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 99 (5), 511-20.
116. Strindhall, J., Nilsson, B.O., Lofgren, S. et al. (2007) No immune risk profile among individuals who reach 100 years of age: Findings from the Swedish NONA immune longitudinal study. Experimental Gerontology, 42 (8), 753-61.
117. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (1992) Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. The New England Journal of Medicine, 326 (4), 213-20.
118. Studies of Ocular Complications of AIDS Research Group ACTG (1996) Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Archives of Ophthalmology, 114 (1), 23-33.
119. Sullivan, V., Talarico, C.L., Stanat, S.C. et al. (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 358 (6382), 162-64.
120. Thorne, J.E., Holbrook, J.T., Jabs, D.A. et al. (2007) Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology, 114 (3), 591-98.
121. Trzonkowski, P., Mysliwska, J., Szmit, E. et al. (2003) Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine, 21 (25-26), 3826-36.
122. Vamum, S.M., Streblow, D.N., Monroe, M.E. et al. (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. Journal of Virology, 78 (20), 10960-66.
123. van den Berg, A.P., Klompmaker, I.J., Haagsma, E.B. et al. (1991) Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. The Journal of Infectious Diseases, 164 (2), 265-70.
124. Wertheim, P., Buurman, C., Geelen, J., van der, N.J. (1983) Transmission of cytomegalovirus by renal allograft demonstrated by restriction enzyme analysis. Lancet, 30 (1/8331), 980-1.
125. Whitley, R.J., Cloud, G., Gruber, W. et al. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1997) Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. The Journal of Infectious Diseases, 175 (5), 1080-86.
126. Winston, D.J., Huang, E.S., Miller, M.J. et al. (1985) Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Annals of Internal Medicine, 102 (1), 16-20.
127. Winston, D.J., Ho, W.G., Bartoni, K. et al. (1993) Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial. Annals of Internal Medicine, 118 (3), 179-84.
128. Winston, D.J., Wirin, D., Shaked, A. and Busuttil, R.W. (1995) Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet, 346 (8967), 69-74.
129. Wohl, D.A., Kendall, M.A., Andersen, J. et al. (unpublished) Pre-emptive valganciclovir fails to prevent CMV end-organ disease in patients with CMV viremia: results of ACTG protocol A5030.
130. Yeager, A.S., Palumbo, P.E., Malachowski, N. et al. (1983) Sequelae of maternally derived cytomegalovirus infections in premature infants. The Journal of Pediatrics, 102 (6), 918-22.
131. Yurochko, A.D., Hwang, E.S., Rasmussen, L. et al. (1997) The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. Journal of Virology, 71 (7), 5051-59.